Drug Patents owned by Scynexis
1. Drug name - BREXAFEMME
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8188085 | SCYNEXIS | Antifungal agents |
Aug, 2030
(7 years from now) | |
| US10174074 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(12 years from now) | |
| US10927142 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(12 years from now) | |
| CN102176827B | SCYNEXIS | Antifungal Preparation |
Aug, 2029
(6 years from now) | |
| CN102176827A | SCYNEXIS | Antifungal Agents |
Aug, 2029
(6 years from now) | |
| CN104877001B | SCYNEXIS | Antifungal Preparation |
Aug, 2029
(6 years from now) | |
| CN104877001A | SCYNEXIS | Anti-Fungal Formulation |
Aug, 2029
(6 years from now) | |
| IN201100410P2 | SCYNEXIS | Antifungal Agents |
Aug, 2029
(6 years from now) | |
| IN304757B | SCYNEXIS | Triazole-Substituted Derivatives Of Enfumafungin As Antifungal Agents |
Aug, 2029
(6 years from now) | |
| EP3247711B1 | SCYNEXIS | Novel Salts And Polymorphs Of Scy-078 |
Jan, 2036
(13 years from now) | |
| EP3247711A1 | SCYNEXIS | Novel Salts And Polymorphs Of Scy-078 |
Jan, 2036
(13 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10370406 | SCYNEXIS | Salts and polymorphs of SCY-078 |
Jan, 2035
(12 years from now) | |
Drugs and Companies using IBREXAFUNGERP CITRATE ingredient
Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 150MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.